Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1-Reference-Cited by-同舟云学术

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1

Published:2020-11 Issue:4 Volume: Page:79-90
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Hemming Matthew L.¹²,Nathenson Michael J.²,Lin Jia-Ren³⁴,Mei Shaolin³⁴,Du Ziming³⁵,Malik Karan²,Marino-Enriquez Adrian⁵,Jagannathan Jyothi P.⁶,Sorger Peter K.³⁴⁷,Bertagnolli Monica⁸,Sicinska Ewa⁹,Demetri George D.²⁴,Santagata Sandro³⁴⁵

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

2. Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

3. Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA

4. Ludwig Center at Harvard, Boston, MA

5. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

6. Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, and Department of Radiology, Brigham and Women's Hospital, Boston, MA

7. Department of Systems Biology, Harvard Medical School, Boston, MA

8. Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

9. Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.19.00287

Reference28 articles.

1. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

2. Efficacy of Larotrectinib inTRKFusion–Positive Cancers in Adults and Children

3. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

4. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

5. NTRK fusion-positive cancers and TRK inhibitor therapy

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies;Journal of Medicinal Chemistry;2024-08-15

2. Prognostic value of structural variants in early breast cancer patients;npj Breast Cancer;2024-07-27

3. Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway;Cancer Medicine;2024-06

4. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivoLMNA::NTRK1‐rearranged soft‐tissue sarcoma cell model;The Journal of Pathology;2024-04-12

5. Primary NTRK-rearranged Spindle Cell Neoplasm of the Gastrointestinal Tract: A Clinicopathological and Molecular Analysis of 8 Cases;American Journal of Surgical Pathology;2024-03-25